

1 **Investigating Causal Relationships between Inflammatory Bowel Disease and**
2 **Autism Spectrum Disorder: A Bidirectional Two-sample Mendelian**
3 **Randomization Study**

4 Ruijie Zeng, MBBS^{†1,2}, Rui Jiang, BS^{†1,3}, Jinghua Wang, MD^{†1,4}, Jie Yang, MS¹, Huihuan Wu,
5 MBBS^{1,3}, Zewei Zhuo, BS^{1,5}, Qi Yang, BS¹, Jingwei Li, MS¹, Songyan Liao, PhD^{6,7}, Hung-Fat
6 Tse, MD, PhD^{*6,7}, Weihong Sha, MD^{*1,8,3,5}, Hao Chen, MD^{*1,8,3,5}

7 ¹ Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong
8 Academy of Medical Sciences, Guangzhou 510080, China

9 ² Shantou University Medical College, Shantou 515000, Guangdong, China

10 ³ School of Medicine, South China University of Technology, Guangzhou 510006, China

11 ⁴ Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy
12 of Medical Sciences, Guangzhou 510080, China

13 ⁵ School of Bioscience and Bioengineering, South China University of Technology,
14 Guangzhou 510006, China

15 ⁶ Department of Medicine, The University of Hong Kong, Hong Kong SAR 999077, China

16 ⁷ Shenzhen Institutes of Research and Innovation, The University of Hong Kong, Shenzhen
17 518000, China

18 ⁶ The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515,
19 China

20 ***Correspondence:**

21 Prof. Hung-Fat Tse, Department of Medicine, The University of Hong Kong, Hong Kong SAR
22 999077, China;

23 E-mail: hftse@hku.hk

- 1 Prof. Weihong Sha, Department of Gastroenterology, Guangdong Provincial People's
- 2 Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China;
- 3 E-mail: shaweihong@gdph.org.cn
- 4 Prof. Hao Chen, Department of Gastroenterology, Guangdong Provincial People's Hospital,
- 5 Guangdong Academy of Medical Sciences, Guangzhou 510080, China;
- 6 E-mail: chenhao@gdph.org.cn
- 7 †: These authors contributed equally to this work

1 **Abstract**

2 **Background and aims**

3 Inflammatory bowel disease (IBD) is usually comorbid with psychological disorders.
4 Emerging observational studies have indicated the association between autism spectrum
5 disorder (ASD) and IBD, including Crohn's disease (CD) and ulcerative colitis (UC), whereas
6 the causality remains unknown. Our study aimed to explore the causal association between
7 IBD and ASD using bidirectional two-sample Mendelian randomization (MR) design.

8 **Methods**

9 Summary-level data from large-scale genome-wide association (GWAS) studies of IBD
10 (International Inflammatory Bowel Disease Genetics Consortium, $N_{\text{cases}}=25,042$,
11 $N_{\text{controls}}=34,915$) and ASD (Integrative Psychiatric Research-Psychiatric Genomics
12 Consortium, $N_{\text{cases}}=18,382$, $N_{\text{controls}}=27,969$) were retrieved. Gene variants for IBD and ASD
13 were selected as instrumental variables. MR analyses were performed mainly including the
14 inverse-variance-weighted method with a series of sensitivity tests.

15 **Results**

16 Genetic predisposition to IBD was associated with a high risk of ASD (odds ratio [OR] = 1.03,
17 95% confidence interval [CI] = 1.01-1.06, $P = 0.01$; OR [95% CI]: 1.03 [1.01-1.05], $P = 0.02$
18 for CD; OR [95% CI]: 1.03 [1.01-1.07], $P = 0.04$ for UC). In contrast, no causal association
19 was found for the genetic liability to ASD on IBD.

20 **Conclusions**

21 Our findings reveal that genetically predicted IBD is causally related to ASD, whereas the
22 causal association of ASD on IBD is not supported. Our study highlights the early screening

1 and surveillance of psychological symptoms, as well as sustaining support for patients with

2 IBD. Further investigations on age-specific groups are warranted.

3 **Keywords**

4 Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Autism spectrum disorder,

5 Mendelian randomization

6

1 **1. Introduction**

2 Inflammatory bowel disease (IBD), mainly classified into two subtypes including Crohn's
3 disease (CD) and ulcerative colitis (UC), is a chronic relapsing and remitting disease
4 contributed by the dysregulated immune system and the commensal ecosystem with no cure
5 (Graham and Xavier, 2020). Although the incidence of IBD in western countries is relatively
6 stable, newly industrialized countries are still in the stage of accelerating incidence (Kaplan
7 and Windsor, 2021).

8 A wide range of comorbid conditions, including metabolic syndrome, cardiovascular
9 disorders, and neuropsychological diseases, have been observed to coexist with IBD (Argollo
10 et al., 2019). Increasing evidence has indicated that poor psychological health might
11 aggravate the disease course of IBD (Fairbrass et al., 2021; Gracie et al., 2016). Autism
12 spectrum disorder (ASD) is a neurodevelopmental disease with impaired social
13 communication skills as well as restricted and repetitive behaviors (American Psychiatric
14 Association and Association, 2013). The suicide attempt and deaths from un-natural causes
15 of patients with ASD are approximately 3-fold higher than the generally population
16 (Catalá-López et al., 2022; Kõlves et al., 2021; Xu et al., 2018). Complex mechanisms
17 including genetic and environmental factors with gene-environment interactions are involved
18 in the development of ASD (Taylor et al., 2020).

19 Emerging recognition of the associations between IBD and ASD has been raised. Among
20 the patients with IBD, a national Swedish cohort study observes a 40% increased risk of
21 developing ASD (Butwicka et al., 2019). For the patients with ASD, a recent meta-analysis
22 involving over 11 million participants indicates that the risk of subsequently developed IBD is

1 increased by approximately 66% (Kim et al., 2022). Interactions between gut microbiota and
2 the brain also indicate the possible involvement of altered gut microbiome in the
3 pathogenesis of ASD (Bundgaard-Nielsen et al., 2020). The dysregulations in composition,
4 ecology, and functionality of gut microbiome in children with ASD irrespective of diet have
5 been identified (Wan et al., 2022).

6 Although increasing evidence has supported the linkages, the causality and sequential
7 temporality between IBD and ASD remains unclear. In this study, using the bidirectional
8 two-sample MR approach (**Figure 1**), which can avoid confounding, reverse causation, and
9 various biases in observational epidemiological studies (Davey Smith and Hemani, 2014), we
10 aimed to reveal the causal relationship between IBD and ASD.

11

12 **2. Methods**

13 **2.1 Study design**

14 A bidirectional two-sample MR design was used to evaluate the causal relationship between
15 IBD and ASD (**Figure 1**). On the one hand, the causality of IBD on ASD was examined by the
16 MR method. On the other hand, the causality of ASD on IBD was evaluated by the MR
17 method in reverse. This study was based on de-identified summary-level genome-wide
18 association study (GWAS) data, and therefore our study did not require ethical approval or
19 consent.

20

21 **2.2 Data sources**

22 The summary-level GWAS data of patients with IBD, including UC and CD, was extracted

1 from the study by the International Inflammatory Bowel Disease Genetics Consortium
2 (IIBDGC) (de Lange et al., 2017). The IIBDGC study involves 59,957 individuals (25,042
3 cases and 34,915 controls) for IBD, 40,266 individuals (12,194 cases and 28,072 controls) for
4 CD, and 45,975 individuals (12,366 cases and 33,609 controls) for UC. Summary data of
5 ASD patients were obtained from a study of Integrative Psychiatric Research-Psychiatric
6 Genomics Consortium (iPSYCH-PGC) (Grove et al., 2019). The iPSYCH-PGC study includes
7 46,351 individuals (18,382 cases and 27,969 controls) with ASD. All of the patients and
8 control subjects for IBD and ASD were of European ancestry.

9

10 **2.3 Mendelian randomization analysis**

11 MR was performed in R (V 4.1.0) using the TwoSampleMR package (Hemani et al., 2018).
12 The genetic instruments were selected based on the genome-wide significance threshold (P
13 $< 5 \times 10^{-8}$) associated with each trait, and further underwent the clumping process using a
14 threshold of $r^2 < 0.001$ and distance (kb) = 10 000 of linkage disequilibrium (LD). After
15 harmonizing the exposure and outcome datasets, palindromic SNPs with intermediate allele
16 frequencies were removed. If the SNP was not identified in the outcome dataset, a proxy
17 single nucleotide polymorphism (SNP; $r^2 > 0.8$) was utilized, or the SNP was discarded when
18 no proxy was available. F statistics for each instrument were estimated by $F = \beta^2/SE^2$, and an
19 F statistic < 10 was regarded as insufficiently informative for further analysis (Li and Martin,
20 2002). Inverse variance weighted (IVW) regression was principally chosen for inferring
21 causality, assuming all genetic variants were valid instruments (Burgess et al., 2013).

22

1 **2.4 Sensitivity analysis**

2 Heterogeneity was further evaluated using Cochran's Q test and the I^2 index, and it was
3 considered existing using the criteria of Cochran's Q test's $P < 0.05$ and $I^2 > 50\%$. The causal
4 effects were further assessed by the MR-Egger, weighted-median (WM), and weighted
5 mode-based estimate (WMBE) methods. MR-Egger intercept and Mendelian Randomization
6 Pleiotropy Residual Sum and Outlier (MR-PRESSO) tests were used to detect potential
7 horizontal pleiotropy (Verbanck et al., 2018). MR-PRESSO was also used to identify
8 horizontal pleiotropic outliers. Leave-one-out analysis was performed to identify potential
9 outliers affecting the overall estimates by excluding one SNP at a time. The causality was
10 established when the following criteria were met: IVW passed the statistical significance ($P <$
11 0.05) and one of the following assumptions was achieved: 1) no detected heterogeneity,
12 and MR-Egger, WM, and WMBE were directionally identical; 2) if heterogeneity was detected,
13 it could be corrected by MR-PRESSO, while less than 50% of the instruments were outliers; 3)
14 heterogeneity existed with more than 50% of the instruments detected as outliers, while
15 results from MR Egger and WM were significant and directionally identical, with WMBE in the
16 same direction (Marini et al., 2020; Verbanck et al., 2018).

17

18 **3. Results**

19 **3.1 Selection of instrumental variables (IVs)**

20 LD-independent SNPs for IBD were obtained following the clumping, and the following
21 conditions were used to further remove the listed SNPs: 1) a desired SNP was not detected
22 during extracting SNPs from the outcomes, and a proxy in LD could not be identified from the

1 outcome; 2) for ambiguous SNPs or palindromic SNPs with ambiguous strands, no correction
2 could be made. **Supplementary Table S2** lists the SNPs selected as IV for further analysis. *F*
3 statistics for each IV-exposure association were larger than 10 (ranging from 29.80 to 500.60).
4 Thus, the weak instrumental variable bias was less likely to exist in our study.

5

6 **3.2 Two-sample Mendelian randomization analysis for causality of IBD on ASD**

7 The estimates of causal effect of IBD on ASD were summarized in **Figure 2** and
8 **Supplementary Figure S1. Table 1** illustrates the results from the examination of
9 heterogeneity. Genetic liability to IBD was significantly associated with an increased risk of
10 ASD, and no outlier was detected by MR-PRESSO test (Inverse variance weighted [IVW, 95%
11 CI]: 1.03 [1.01-1.06], *P* = 0.01; all results from the methods were directionally consistent;
12 **Figure 2, Table 1, Supplementary Figure 1A**). Scatter plot was also used to demonstrate
13 the estimates of causal effects (**Figure 3A**). The causal estimate of IBD on ASD was without
14 heterogeneity (Cochran's *Q* = 98.10, *P* = 0.53, **Table 1**) and remained robust with
15 leave-one-out test (**Supplementary Figure S2A**). The funnel plots also illustrated that the
16 evidence of heterogeneity for IBD on ASD was not visually significant (**Supplementary**
17 **Figure S3A**). No significant evidence of horizontal pleiotropy for the causality of IBD on ASD
18 was found (MR-Egger intercept = -0.002, SE = 0.004, *P* = 0.54; MR-PRESSO global test *P* =
19 0.56; **Supplementary Table S3**).

20

21 **3.3 Two-sample Mendelian randomization analysis for causality of CD and UC on ASD**

22 We further evaluated the causal effects of the two IBD subtypes, CD and UC, on ASD.

1 Genetic susceptibility to CD or UC was significantly increased the risk of ASD, and no outlier
2 was detected by MR-PRESSO test (IVW [95% CI]: 1.03 [1.01-1.05], $P = 0.02$ for CD; IVW [95%
3 CI]: 1.03 [1.01-1.07], $P = 0.04$ and Weighted median [95% CI]: 1.05 [1.01-1.10], $P = 0.04$ for
4 UC), all results from the methods were directionally consistent; **Figure 2, Table 1,**
5 **Supplementary Figure 1B-C**). Scatter plots were also used to show the estimates of causal
6 effects (**Figure 3B-C**). The causal estimate of CD or UC on ASD was without heterogeneity
7 (Cochran's $Q = 64.43$, $P = 0.78$ for CD; Cochran's $Q = 62.25$, $P = 0.08$ for UC; **Table 1**). The
8 causality of CD on ASD remained robust (**Supplementary Figure S2B**), while that of UC on
9 ASD was affected by certain SNPs in leave-one-out tests (**Supplementary Figure S2C**). The
10 funnel plots were also shown in **Supplementary Figure S3B-C**. No significant evidence of
11 horizontal pleiotropy for the causal association of CD or UC on ASD was found (MR-Egger
12 intercept = -0.002, SE = -0.005, $P = 0.47$ and MR-PRESSO global test $P = 0.10$ for CD;
13 MR-Egger intercept = 0.0007, SE = 0.005, $P = 0.89$ and MR-PRESSO global test $P = 0.78$ for
14 UC; **Supplementary Table S3**).

15

16 **3.4 Two-sample Mendelian randomization analysis for the causality of ASD on IBD**

17 The causal associations of ASD on IBD, including CD and UC, were evaluated. No evidence
18 of causal effects of ASD on IBD, CD, or UC were identified (Wald ratio [95% CI]: 1.04
19 [0.77-1.40], $P = 0.80$ for IBD; Wald ratio [95% CI]: 1.35 [0.92-1.99], $P = 0.12$ for CD; Wald
20 ratio [95% CI]: 0.95 [0.65-1.39], $P = 0.79$ for UC; **Supplementary Table S4**).

21

22 **4 Discussion**

1 In the present study, we investigated the causal relationship between IBD and ASD using MR.
2 Our findings indicate that genetic susceptibility to IBD, including both CD and UC, is
3 associated with an increased risk of ASD, whereas genetic liability to ASD does not lead to
4 IBD.

5 Previous observational studies suggest the comorbidity of IBD and ASD (Alexeeff et al.,
6 2017; Butwicka et al., 2019; Doshi-Velez et al., 2015; Kohane et al., 2012; Lee et al., 2018). A
7 cross-sectional study involving over 14,000 patients with ASD indicates that the prevalence of
8 IBD among patients with ASD is higher than that in the overall hospital population (0.83% vs.
9 0.54%) (Kohane et al., 2012). A cohort study totaling over 60,000 ASD cases in the United
10 States demonstrates that the prevalence of IBD in patients with ASD is higher than that of the
11 control population or nationally reported rates (Doshi-Velez et al., 2015). In another
12 retrospective study from the TRICARE Management Activity Military Health System database
13 involving over 48,000 ASD cases, researchers identify an enhanced risk of IBD diagnosis in
14 children with ASD (OR = 1.67, 95% CI = 1.31-2.13) (Lee et al., 2018). A meta-analysis
15 involving over 11 million participants confirms that ASD is epidemiologically associated with
16 incident IBD (OR = 1.66, 95% CI = 1.25-2.21), including CD (OR = 1.47, 95% CI = 1.15-1.88)
17 and UC (OR = 1.91, 95%CI = 1.41-2.6) (Kim et al., 2022). Researchers assumed a temporal
18 order of IBD diagnosis subsequent to ASD diagnosis, indicating that ASD might increase the
19 risk of IBD (Kim et al., 2022). Among patients with IBD, based on a Northern California cohort,
20 it is observed that the risk of ASD is increased (odds ratio [OR] = 1.34, 95% confidence
21 interval [CI] = 1.22-1.40) (Alexeeff et al., 2017). A more recent study from a national Swedish
22 cohort demonstrates that patients with IBD is significantly associated with an increased risk of

1 developing ASD (hazard ratio [HR] = 1.40, 95% CI = 1.10-1.70) (Butwicka et al., 2019). By
2 leveraging bi-directional MR design, our study reveals that the causality of ASD on IBD is
3 unfounded. Instead, IBD could causally increase the risk of ASD.

4 The psychological status of patients with IBD has long been concerned, and plenty of
5 patients with IBD are comorbid with neuropsychological disorders (Gracie et al., 2019). In
6 current clinical guidelines for IBD from American College of Gastroenterology and British
7 Society of Gastroenterology, only screening for depression and anxiety is mentioned, and
8 psychological interventions for IBD patients are weakly recommended (Farraye et al., 2017;
9 Lamb et al., 2019). Although observational studies have indicated the association between
10 IBD with depression or schizophrenia, research by MR approaches eventually do not support
11 the causality of IBD on the two psychological disorders (Luo et al., 2022; Qian et al., 2022). In
12 contrast, our study suggests the causality of IBD on ASD, implying that awareness and
13 screening for ASD and other psychological disorders among patients with IBD are warranted.
14 Psychological supports and interventions might also be needed to help maintain the mental
15 health and improve the prognosis of patients with IBD.

16 The mean age of ASD diagnosis is 60.5 months, with a range from 30.9 to 234.6 months,
17 according to a recent study involving 55 cohorts from 35 countries (van't Hof et al., 2021). For
18 children with IBD, 4% and 18% of them present before age 5 and 10 years, respectively
19 (Rosen et al., 2015). Patients with IBD, especially the children, often present with more
20 insidious and non-specific symptoms, and can even be asymptomatic, which leads to
21 common delays in the diagnosis of IBD (Ajbar et al., 2022; Rosen et al., 2015). Therefore, the
22 significance of surveillance for ASD among patients with childhood-onset IBD is highlighted.

1 The ages at diagnosis of the populations with IBD or ASD used in this study are partially
2 overlapped in childhood age, and the causal effects in our study might be underestimated
3 since summary data based on age stratification is currently unavailable.

4 One strength of our study is that using the bi-directional two-sample MR approach, we
5 revealed the causality of IBD on ASD for the first time. Compared to previous observational
6 studies, our results are less affected by potential confounding, reverse causation, and other
7 biases that can generate their associations. Additionally, a series of sensitivity analyses were
8 conducted and confirmed that our results were robust. However, several limitations need to
9 be mentioned. Our research is limited to individuals of European ancestry, restricting the
10 generalizability of our conclusions to other ancestries. In addition, despite non-detected
11 heterogeneity and horizontal pleiotropy, the causal effect of UC on ASD was affected by
12 certain SNPs in the leave-one-out analysis, and therefore the findings in this study warrant
13 further validation by larger-scale and more powerful datasets. Moreover, subgroup analysis
14 stratified by the baseline characteristics, for example, age and sex, was not available due to
15 the use of summary-level statistics.

16 In summary, the present study reveals that genetically predicted IBD is causally related
17 to ASD, whereas the causal association of ASD on IBD is not supported. Our study signifies
18 the early screening and surveillance of psychological symptoms, as well as sustaining
19 support for patients with IBD. Further explorations on age-stratified groups are warranted.

20

21 **Data sharing statement**

22 GWAS summary statistics are accessible from the original manuscript of each study in

1 **Supplementary Table 1.** Code used in this study is available from the corresponding authors
2 upon reasonable request.

3

4 **Conflict of Interest Statement**

5 The authors declared no conflict of interest.

6

7 **Acknowledgement**

8 This work is supported by the National Natural Science Foundation of China (82171698,
9 82170561, 81300279, 81741067, 82100238), the Natural Science Foundation for
10 Distinguished Young Scholars of Guangdong Province (2021B1515020003), the Guangdong
11 Basic and Applied Basic Research Foundation (2022A1515012081), the Climbing Program of
12 Introduced Talents and High-level Hospital Construction Project of Guangdong Provincial
13 People's Hospital (DFJH201923, DFJH201803, KJ012019099, KJ012021143,
14 KY012021183).

15

16 **Author contributions**

17 Conceptualization and design: HFT, WHS, HC; Administrative support: HFT, WHS, HC;
18 Funding acquisition: WHS, HC, JHW; Collection and assembly of data: RJZ, RJ, JHW; Data
19 analysis and interpretation: RJZ, RJ, JHW, JY, HHW, ZWZ, QY, JWJ, SYL; Manuscript
20 writing-original draft: RJZ, RJ, JHW. Manuscript writing-review & editing: JY, HHW, ZWZ, QY,
21 JWJ, KHG, SYL, HFT, WHS, HC. All authors reviewed and approved the final manuscript. All

- 1 authors had full access to all the data in the study and had final responsibility for the decision
- 2 to submit for publication.

1 **References**

- 2 Ajbar, A., Cross, E., Matoi, S., Hay, C.A., Baines, L.M., Saunders, B., Farmer, A.D., Prior, J.A.,
3 2022. Diagnostic Delay in Pediatric Inflammatory Bowel Disease: A Systematic Review.
4 *Digestive Diseases and Sciences*, 1-11.
- 5 Alexeeff, S.E., Yau, V., Qian, Y., Davignon, M., Lynch, F., Crawford, P., Davis, R., Croen, L.A.,
6 2017. Medical Conditions in the First Years of Life Associated with Future Diagnosis of ASD
7 in Children. *J Autism Dev Disord* 47, 2067-2079.
- 8 American Psychiatric Association, D., Association, A.P., 2013. Diagnostic and statistical
9 manual of mental disorders: DSM-5. American psychiatric association Washington, DC.
- 10 Argollo, M., Gilardi, D., Peyrin-Biroulet, C., Chabot, J.-F., Peyrin-Biroulet, L., Danese, S.,
11 2019. Comorbidities in inflammatory bowel disease: a call for action. *The Lancet*
12 *Gastroenterology & Hepatology* 4, 643-654.
- 13 Bundgaard-Nielsen, C., Knudsen, J., Leutscher, P.D., Lauritsen, M.B., Nyegaard, M.,
14 Hagstrøm, S., Sørensen, S., 2020. Gut microbiota profiles of autism spectrum disorder and
15 attention deficit/hyperactivity disorder: A systematic literature review. *Gut Microbes* 11,
16 1172-1187.
- 17 Burgess, S., Butterworth, A., Thompson, S.G., 2013. Mendelian randomization analysis with
18 multiple genetic variants using summarized data. *Genet Epidemiol* 37, 658-665.
- 19 Butwicka, A., Olén, O., Larsson, H., Halfvarson, J., Almqvist, C., Lichtenstein, P., Serlachius,
20 E., Frisé, L., Ludvigsson, J.F., 2019. Association of Childhood-Onset Inflammatory Bowel
21 Disease With Risk of Psychiatric Disorders and Suicide Attempt. *JAMA Pediatr* 173, 969-978.
- 22 Catalá-López, F., Hutton, B., Page, M.J., Driver, J.A., Ridao, M., Alonso-Arroyo, A., Valencia,

- 1 A., Macías Saint-Gerons, D., Tabarés-Seisdedos, R., 2022. Mortality in Persons With Autism
2 Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder: A Systematic Review and
3 Meta-analysis. *JAMA Pediatr* 176, e216401.
- 4 Davey Smith, G., Hemani, G., 2014. Mendelian randomization: genetic anchors for causal
5 inference in epidemiological studies. *Hum Mol Genet* 23, R89-98.
- 6 de Lange, K.M., Moutsianas, L., Lee, J.C., Lamb, C.A., Luo, Y., Kennedy, N.A., Jostins, L.,
7 Rice, D.L., Gutierrez-Achury, J., Ji, S.G., Heap, G., Nimmo, E.R., Edwards, C., Henderson, P.,
8 Mowat, C., Sanderson, J., Satsangi, J., Simmons, A., Wilson, D.C., Tremelling, M., Hart, A.,
9 Mathew, C.G., Newman, W.G., Parkes, M., Lees, C.W., Uhlig, H., Hawkey, C., Prescott, N.J.,
10 Ahmad, T., Mansfield, J.C., Anderson, C.A., Barrett, J.C., 2017. Genome-wide association
11 study implicates immune activation of multiple integrin genes in inflammatory bowel disease.
12 *Nat Genet* 49, 256-261.
- 13 Doshi-Velez, F., Avillach, P., Palmer, N., Bousvaros, A., Ge, Y., Fox, K., Steinberg, G., Spettell,
14 C., Juster, I., Kohane, I., 2015. Prevalence of inflammatory bowel disease among patients
15 with autism spectrum disorders. *Inflammatory bowel diseases* 21, 2281-2288.
- 16 Fairbrass, K.M., Gracie, D.J., Ford, A.C., 2021. Longitudinal follow-up study: effect of
17 psychological co-morbidity on the prognosis of inflammatory bowel disease. *Alimentary*
18 *Pharmacology & Therapeutics* 54, 441-450.
- 19 Farraye, F.A., Melmed, G.Y., Lichtenstein, G.R., Kane, S.V., 2017. ACG Clinical Guideline:
20 Preventive Care in Inflammatory Bowel Disease. *Am J Gastroenterol* 112, 241-258.
- 21 Gracie, D.J., Hamlin, P.J., Ford, A.C., 2019. The influence of the brain-gut axis in
22 inflammatory bowel disease and possible implications for treatment. *The Lancet*

- 1 Gastroenterology & Hepatology 4, 632-642.
- 2 Gracie, D.J., Williams, C.J., Sood, R., Mumtaz, S., Bholah, H.M., Hamlin, J.P., Ford, A.C.,
3 2016. Poor correlation between clinical disease activity and mucosal inflammation, and the
4 role of psychological comorbidity, in inflammatory bowel disease. Official journal of the
5 American College of Gastroenterology| ACG 111, 541-551.
- 6 Graham, D.B., Xavier, R.J., 2020. Pathway paradigms revealed from the genetics of
7 inflammatory bowel disease. Nature 578, 527-539.
- 8 Grove, J., Ripke, S., Als, T.D., Mattheisen, M., Walters, R.K., Won, H., Pallesen, J., Agerbo,
9 E., Andreassen, O.A., Anney, R., Awashti, S., Belliveau, R., Bettella, F., Buxbaum, J.D.,
10 Bybjerg-Grauholm, J., Bækvad-Hansen, M., Cerrato, F., Chambert, K., Christensen, J.H.,
11 Churchhouse, C., Dellenvall, K., Demontis, D., De Rubeis, S., Devlin, B., Djurovic, S.,
12 Dumont, A.L., Goldstein, J.I., Hansen, C.S., Hauberg, M.E., Hollegaard, M.V., Hope, S.,
13 Howrigan, D.P., Huang, H., Hultman, C.M., Klei, L., Maller, J., Martin, J., Martin, A.R., Moran,
14 J.L., Nyegaard, M., Nærland, T., Palmer, D.S., Palotie, A., Pedersen, C.B., Pedersen, M.G.,
15 dPoterba, T., Poulsen, J.B., Pourcain, B.S., Qvist, P., Rehnström, K., Reichenberg, A.,
16 Reichert, J., Robinson, E.B., Roeder, K., Roussos, P., Saemundsen, E., Sandin, S.,
17 Satterstrom, F.K., Davey Smith, G., Stefansson, H., Steinberg, S., Stevens, C.R., Sullivan,
18 P.F., Turley, P., Walters, G.B., Xu, X., Stefansson, K., Geschwind, D.H., Nordentoft, M.,
19 Hougaard, D.M., Werge, T., Mors, O., Mortensen, P.B., Neale, B.M., Daly, M.J., Børglum, A.D.,
20 2019. Identification of common genetic risk variants for autism spectrum disorder. Nat Genet
21 51, 431-444.
- 22 Hemani, G., Zheng, J., Elsworth, B., Wade, K.H., Haberland, V., Baird, D., Laurin, C.,

1 Burgess, S., Bowden, J., Langdon, R., Tan, V.Y., Yarmolinsky, J., Shihab, H.A., Timpson, N.J.,
2 Evans, D.M., Relton, C., Martin, R.M., Davey Smith, G., Gaunt, T.R., Haycock, P.C., 2018.
3 The MR-Base platform supports systematic causal inference across the human phenome.
4 *Elife* 7.
5 Kaplan, G.G., Windsor, J.W., 2021. The four epidemiological stages in the global evolution of
6 inflammatory bowel disease. *Nature reviews Gastroenterology & hepatology* 18, 56-66.
7 Kim, J.Y., Choi, M.J., Ha, S., Hwang, J., Koyanagi, A., Dragioti, E., Radua, J., Smith, L.,
8 Jacob, L., de Pablo, G.S., 2022. Association between autism spectrum disorder and
9 inflammatory bowel disease: A systematic review and meta-analysis. *Autism Research* 15,
10 340-352.
11 Kohane, I.S., McMurry, A., Weber, G., MacFadden, D., Rappaport, L., Kunkel, L., Bickel, J.,
12 Wattanasin, N., Spence, S., Murphy, S., Churchill, S., 2012. The co-morbidity burden of
13 children and young adults with autism spectrum disorders. *PLoS One* 7, e33224.
14 Kølves, K., Fitzgerald, C., Nordentoft, M., Wood, S.J., Erlangsen, A., 2021. Assessment of
15 Suicidal Behaviors Among Individuals With Autism Spectrum Disorder in Denmark. *JAMA*
16 *Netw Open* 4, e2033565.
17 Lamb, C.A., Kennedy, N.A., Raine, T., Hendy, P.A., Smith, P.J., Limdi, J.K., Hayee, B., Lomer,
18 M.C.E., Parkes, G.C., Selinger, C., Barrett, K.J., Davies, R.J., Bennett, C., Gittens, S., Dunlop,
19 M.G., Faiz, O., Fraser, A., Garrick, V., Johnston, P.D., Parkes, M., Sanderson, J., Terry, H.,
20 Gaya, D.R., Iqbal, T.H., Taylor, S.A., Smith, M., Brookes, M., Hansen, R., Hawthorne, A.B.,
21 2019. British Society of Gastroenterology consensus guidelines on the management of
22 inflammatory bowel disease in adults. *Gut* 68, s1-s106.

- 1 Lee, M., Krishnamurthy, J., Susi, A., Sullivan, C., Gorman, G.H., Hisle-Gorman, E.,
- 2 Erdie-Lalena, C.R., Nylund, C.M., 2018. Association of autism spectrum disorders and
- 3 inflammatory bowel disease. *Journal of autism and developmental disorders* 48, 1523-1529.
- 4 Li, B., Martin, E.B., 2002. An approximation to the F distribution using the chi-square
- 5 distribution. *Computational statistics & data analysis* 40, 21-26.
- 6 Luo, J., Xu, Z., Noordam, R., van Heemst, D., Li-Gao, R., 2022. Depression and Inflammatory
- 7 Bowel Disease: A Bidirectional Two-sample Mendelian Randomization Study. *J Crohns*
- 8 *Colitis* 16, 633-642.
- 9 Marini, S., Merino, J., Montgomery, B.E., Malik, R., Sudlow, C.L., Dichgans, M., Florez, J.C.,
- 10 Rosand, J., Gill, D., Anderson, C.D., 2020. Mendelian randomization study of obesity and
- 11 cerebrovascular disease. *Annals of neurology* 87, 516-524.
- 12 Qian, L., He, X., Gao, F., Fan, Y., Zhao, B., Ma, Q., Yan, B., Wang, W., Ma, X., Yang, J., 2022.
- 13 Estimation of the bidirectional relationship between schizophrenia and inflammatory bowel
- 14 disease using the mendelian randomization approach. *NPJ Schizophr* 8, 31.
- 15 Rosen, M.J., Dhawan, A., Saeed, S.A., 2015. Inflammatory bowel disease in children and
- 16 adolescents. *JAMA pediatrics* 169, 1053-1060.
- 17 Taylor, M.J., Rosenqvist, M.A., Larsson, H., Gillberg, C., D'Onofrio, B.M., Lichtenstein, P.,
- 18 Lundström, S., 2020. Etiology of autism spectrum disorders and autistic traits over time.
- 19 *JAMA psychiatry* 77, 936-943.
- 20 van't Hof, M., Tisseur, C., van Berckeleer-Onnes, I., van Nieuwenhuyzen, A., Daniels, A.M.,
- 21 Deen, M., Hoek, H.W., Ester, W.A., 2021. Age at autism spectrum disorder diagnosis: A
- 22 systematic review and meta-analysis from 2012 to 2019. *Autism* 25, 862-873.

- 1 Verbanck, M., Chen, C.Y., Neale, B., Do, R., 2018. Detection of widespread horizontal
2 pleiotropy in causal relationships inferred from Mendelian randomization between complex
3 traits and diseases. *Nat Genet* 50, 693-698.
- 4 Wan, Y., Zuo, T., Xu, Z., Zhang, F., Zhan, H., Dorothy, C., Leung, T.-F., Yeoh, Y.K., Chan, F.K.,
5 Chan, R., 2022. Underdevelopment of the gut microbiota and bacteria species as
6 non-invasive markers of prediction in children with autism spectrum disorder. *Gut* 71,
7 910-918.
- 8 Xu, G., Strathearn, L., Liu, B., Bao, W., 2018. Prevalence of autism spectrum disorder among
9 US children and adolescents, 2014-2016. *Jama* 319, 81-82.
- 10

1 **Figure Legends**

2 **Figure 1. Schematic diagram of two-sample Mendelian randomization (MR) analysis for**
3 **the causality between inflammatory bowel disease (IBD) and autism spectrum disorder**

4 **(ASD).** There are three core assumptions for MR: 1) Assumption 1: the instrumental variants
5 (IVs) should be associated with the exposure (IBD); 2) Assumption 2: the IVs should not be
6 associated with confounders; 3) Assumption 3: the IVs should influence the outcome (ASD)
7 only by the exposure. The causal relationship between IBD and ASD will not be established if
8 any of the assumptions are violated. ASD: autism spectrum disorder; IBD: inflammatory
9 bowel disease; IIBDGC: International Inflammatory Bowel Disease Genetics Consortium;
10 iPSYCH-PGC: Integrative Psychiatric Research-Psychiatric Genomics Consortium; IVW,
11 inverse variance weighted; MR: Mendelian randomization; SNP, single-nucleotide
12 polymorphism.

13 **Figure 2. The causal association of inflammatory bowel disease (IBD), including**
14 **Crohn's disease (CD) and ulcerative colitis (UC), on autism spectrum disorder (ASD).**

15 Error bars indicate the 95% confidence intervals (CIs) for the estimates. CI: confidence
16 interval; IVW: inverse variance weighted.

17 **Figure 3. Scatter plots of the causal association of inflammatory bowel disease (IBD),**
18 **including Crohn's disease (CD) and ulcerative colitis (UC), on autism spectrum**

19 **disorder (ASD). A. IBD on ASD; B. CD on ASD; C. UC on ASD.** The slope of each line
20 indicates the estimation of effects by each method. SNP: single nucleotide polymorphism.

Figure 1




Figure 2






Figure 3

A



B



C




Table 1. Mendelian randomization (MR) analysis for the causality of inflammatory bowel diseases (IBD) on autism spectrum disorder (ASD).

Exposure	Outcome	Method	SNPs	Mendelian randomization		Heterogeneity	
				Odds ratio (95% CI)	P	Q	Q_P
IBD	ASD	IVW	101	1.03 (1.01-1.06)	0.01	98.10	0.53
		MR Egger	101	1.05 (0.99-1.12)	0.12	97.74	0.52
		Weighted median	101	1.04 (0.99-1.08)	0.06		
		Weighted mode	101	1.03 (0.97-1.11)	0.32		
		MR-PRESSO	101	1.03 (1.01-1.06)	0.01		
CD	ASD	IVW	75	1.03 (1.01-1.05)	0.02	64.43	0.78
		MR Egger	75	1.02 (0.96-1.10)	0.50	64.42	0.75
		Weighted median	75	1.02 (0.99-1.06)	0.21		
		Weighted mode	75	1.01 (0.95-1.08)	0.66		
		MR-PRESSO	75	1.03 (1.01-1.05)	0.02		
UC	ASD	IVW	50	1.03 (1.01-1.07)	0.04	62.25	0.08
		MR Egger	50	1.07 (0.97-1.17)	0.17	62.25	0.09
		Weighted median	50	1.05 (1.01-1.10)	0.04		
		Weighted mode	50	1.06 (0.99-1.13)	0.10		
		MR-PRESSO	50	1.03 (1.01-1.07)	0.04		

ASD: autism spectrum disorder; CD: Crohn's disease; CI: confidence interval; IBD: inflammatory bowel disease; IVW: Inverse variance weighted; SNP: single-nucleotide polymorphism; UC: ulcerative colitis.